Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer

Table 2 Logistic regression for BRCA1 versus WT and BRCA2 versus WT: univariate and multivariate analysis

Characteristics		Univariate LR OR (95%CI)	p-value	Multivariate LR^a OR (95%CI)	p-value	Univariate LR OR (95%CI)	p-value	Multivariate LR^a OR (95%CI)	p-value
Characteristics		BRCA1 vs WT				BRCA2 vs WT
Age at diagnosis (years)	<50y	1.0				1.0
Age at diagnosis (years)	≥50y	0.68 (0.34–1.37)	0.283			1.18 (0.61–2.28)	0.624
Tumor grade	1 + 2	1.0				1.0		1.0
Tumor grade	3	6.55 (3.07–13.97)	<.001			2.13 (1.06–4.29)	0.034	2.41 (1.02–5.69)	0.045
Tumor size	< 2 cm	1.0				1.0		–
Tumor size	> = 2 cm	1.90 (.98–3.68)	0.056			1.51 (0.77–2.96)	0.227	–
ER	Negative	1.0				1.0		–
ER	Positive	.11 (.05–.22)	<.001	0.46 (0.09–2.66)	0.400	1.35 (0.62–2.91)	0.449	–
PR	Negative	1.0				1.0		–
PR	Positive	0.14 (0.07–0.30)	<.001	0.35 (0.07–1.87)	0.354	0.96 (0.49–1.85)	0.890	–
HER2	Negative	1.0				1.0		1.0
HER2	Positive	1.06 (.49–2.31)	0.887	1.03 (0.24–4.48)	0.970	5.33 (2.58–11.03)	<.001	5.21 (2.18–12.45)	<.001
CK5	Negative	1.0				1.0		–
CK5	Positive	8.36 (3.50–19.93)	<.001	6.46 (1.52–27.43)	0.011	0.79 (0.23–2.71)	0.705	–
CK14	Negative	1.0				1.0		–
CK14	Positive	3.96 (1.28–12.27)	0.017			0.73 (0.14–3.89)	0.709	–
EGFR	Negative	1.0				1.0
EGFR	Positive	0.73 (.24–2.26)	0.586			0.15 (0.02–1.20)	0.074
CLDN3	Negative	1.0				1.0
CLDN3	Positive	160.50 (20.96–1229.06)	<.001	200.48 (21.52–1867.61)	<.001	8.92 (0.97–81.90)	0.053
CLDN4	Negative	1.0		–		–		–
CLDN4	Positive	3.36 (0.39–28.62)	0.267	–		–		–
CLDN7	Negative	–		–		–		–
CLDN7	Positive	–		–		–		–
E-cadherin	Negative	1.0		–		1.0		1.0
E-cadherin	Positive	0.60 (0.23–1.58)	0.299	–		0.27 (0.11–0.64)	0.003	0.33 (0.11–0.98)	0.046

ISSN: 1471-2407